How One Alzheimer’s Drug Is Changing the U.S. Drug Approval Conversation
After Medicare’s decision to restrict coverage of the controversial new Alzheimer’s drug Aduhelm, we look at how this one drug has forced the nation to reexamine how to balance the needs of desperate patients, incomplete evidence and larger economic realities.
Phil Gutis, Alzheimer’s patient and advocate
Holly Fernandez Lynch, JD, MBe, John Russell Dickson, MD Presidential Assistant Professor of Medical Ethics, University of Pennsylvania
Have a look at some additional resources and a full transcript.
Support this type of journalism today, with a gift.
Follow us on Twitter.
See acast.com/privacy for privacy and opt-out information.